From: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
Outcome
Predictor p-value
> 3 sites
No adjuvant Chemo
Visceral site
Hormonal Receptors Negative
Prior taxanes
Prior Anthra
PFS
0.032
0.00013
0.03
0.009
0.96
0.019
OS
0.99
0.18
0.56
0.66
0.45
0.91